OOIR: Observatory of International Research

Papers

(The TQCC of Biomarker Research is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study	185
Development and validation of predictive models combining cell-Free DNA motifs and protein biomarkers for early detection of esophageal squamous cell carcinoma and precancerous lesion	171
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma	164
Exosomal PSM-E inhibits macrophage M2 polarization to suppress prostate cancer metastasis through the RACK1 signaling axis	143
Unraveling the immune microenvironment in primary CNS lymphoma	133
CardioAtlas: deciphering the single-cell transcriptome landscape in cardiovascular tissues and diseases	124
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes	118
Circulating Tumor DNA from Ascites as an alternative to tumor sampling for genomic profiling in ovarian cancer patients	117
Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting	117
Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma	114
Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer	108
Skin-permeable gold nanoparticles with modifications azelamide monoethanolamine ameliorate inflammatory skin diseases	103
Extracellular vesicle-based liquid biopsy biomarkers and their application in precision immuno-oncology	101
The spatial impact of a Western diet in enriching Galectin-1-regulated Rho, ECM, and SASP signaling in a novel MASH-HCC mouse model	99
Mitochondrial transfer in hematological malignancies	96
Targeting novel regulated cell death: disulfidptosis in cancer immunotherapy with immune checkpoint inhibitors	94
The overlooked trio: sleep duration, sampling time and physical exercise alter levels of olink-assessed blood biomarkers of cardiovascular risk	93
The molecular landscape of the C1498 murine acute myeloid leukemia cell line	92
A machine learning-based model to predict POD24 in follicular lymphoma: a study by the Chinese workshop on follicular lymphoma	92
Dynamic changes of bone microarchitecture and volumetric mineral density assessed by HR-pQCT in patients with cervical cancer after concurrent chemoradiotherapy: a prospective study	92
Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells	91
Multi-omics profiling reveals intrathymic triggers and novel biomarkers in thymoma-associated myasthenia gravis	91
Emerging roles of circular RNAs and enhancer RNAs: new insights into the development and management of neurodegenerative disorders	90
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends	82
The asialoglycoprotein receptor 1 (ASGR1): emerging new roles in health and disease	82

Decoding the microbiome-immune crosstalk in cancer: from mechanisms to therapeutic translation	80
miR-22-Galectin-1 as an integral signaling axis in regulating metabolism and immunity in HCC	79
Unveiling the potential of CLL-1: a promising target for AML therapy	79
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy	75
Circadian rhythm-guided cellular therapy in hematologic malignancies: mechanisms, clinical evidence, and optimization strategies	74
The formation and function of tertiary lymphoid structures	71
INHBA–S100A16 dysregulation enables a non-invasive molecular stratification platform for rapid detection of oral squamous cell carcinoma: results from a large diagnostic case-control study	67
tRNA modifications in cancer: from molecular mechanisms to clinical translation	67
p53 biology and reactivation for improved therapy in MDS and AML	63
The circadian architecture of tumor immunity: mechanistic insights and treatment strategies	63
Monocyte-macrophages modulate intestinal homeostasis in inflammatory bowel disease	62
Copper homeostasis and copper-induced cell death in tumor immunity: implications for therapeutic strategies in cancer immunotherapy	62
Integrated analysis of spatial transcriptomics and CT phenotypes for unveiling the novel molecular characteristics of recurrent and non-recurrent high-grade serous ovarian cancer	60
Plasma ALS and Gal-3BP differentiate early from advanced liver fibrosis in MASLD patients	57
Dysregulation of plasma circulating microRNAs in all-cause and cause-specific cancers: the Rotterdam Study	57
RUNX1 promotes angiogenesis in colorectal cancer by regulating the crosstalk between tumor cells and tumor associated macrophages	57
Identification of urinary bacterial genes as biomarkers for non-invasive diagnosis of renal lupus	57
Correction: Manipulation of cancer cell pyroptosis for therapeutic approaches: challenges and opportunities	56
Proteomic and histopathologic profiling reveal molecular features and clinical biomarkers of coronary atherosclerosis	55
Multiple regulatory events contribute to a widespread circular RNA downregulation in precancer and early stage of colorectal cancer development	55
The role and metabolic adaptations of neutrophils in premetastatic niches	54
Nanoparticles-enhanced CAR-T cell therapy: current advances and future directions	54
Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics	53
STAT3–mediated up-regulation of DAB2 via SRC-YAP1 signaling axis promotes Helicobacter pylori-driven gastric tumorigenesis	53
The involvement of krüppel-like transcription factor 2 in megakaryocytic differentiation induction by phorbol 12-myrestrat 13-acetate	52
The role of BATF in immune cell differentiation and autoimmune diseases	52
Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer	51
Immunophenotypic analysis on circulating T cells for early diagnosis of lung cancer	48
Correction: Long non-coding RNA SLC25A21-AS1 inhibits the development of epithelial ovarian cancer by specifically inducing PTBP3 degradation	48
Transcriptomic analysis of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals distinct subgroups and precision therapy opportunities	47
BRD4: an effective target for organ fibrosis	47
The actively secreted plasma extracellular vesicle troponin (ASPECT) study: circulating troponin in extracellular vesicles across cardiovascular disease cohorts	46
Development of a bispecific antibody that inhibits EGFR and B7H3 in NSCLC	45
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma	45
Whole genome and RNA sequencing analyses for 254 Taiwanese hepatocellular carcinomas	45
Disulfidptosis decoded: a journey through cell death mysteries, regulatory networks, disease paradigms and future directions	45
Glycochenodeoxycholic acid promotes hepatocarcinogenesis by inducing hepatic progenitor cell differentiation into cancer-associated fibroblasts via sphingosine-1-phosphate receptor 2 signalling	44
Isolation and typing techniques for circulating tumor cells	44
The methyltransferase-like proteins as core regulators of nucleic acid modifications and post-translation modification of proteins in disease pathogenesis and therapeutic implications	43
Correction: Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation	43
Long-term kinetics of proviral load in HTLV-1 carriers: defining risk for the development of adult T-cell leukemia/lymphoma	43
Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy and impaired peripheral immunity in non-small cell lung cancer	43
Correction: Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential	43
Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis	42
The cGAS-STING pathway at the crossroads of neuroimmunology: bridging innate immunity to aging and neurodegeneration	42
RBM10 modulation of circRNA biogenesis contributes to its tumor suppressor role in lung adenocarcinoma	41
Advances in measurable residual disease assessment for acute myeloid leukemia: from cytogenetics and molecular biology to assessment of the methylation pattern and surface-enhanced Raman scattering as	41
Comparison of proton therapy and photon therapy for early-stage non-small cell lung cancer: a meta-analysis	40
Mega-scale single-cell profiling reveals novel biomarkers associated with acute GvHD after allogeneic hematopoietic stem cell transplantation	39
Updates on CAR T cell therapy in multiple myeloma	39

Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential	39
Targeting mRNA delivery using bio-inspired hybrid cell membrane-incorporated liposomes: a novel strategy for cancer therapy	39
Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis	39
The essential roles of FXR in diet and age influenced metabolic changes and liver disease development: a multi-omics study	39
Analyzing PKC Gamma (+ 19,506 A/G) polymorphism as a promising genetic marker for HCV-induced hepatocellular carcinoma	38
Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy resistance	38
Single-cell sequencing technology in renal cancer: insights into tumor biology and clinical application	38
The importance of critically short telomere in myelodysplastic syndrome	37
Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer	37
Targeting cGAS-STING pathway for reprogramming tumor-associated macrophages to enhance anti-tumor immunotherapy	36
Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer	36
Identification of a miRNAs signature as potential biomarker of mesenchymal phenotype in neuroblastoma patients	36
Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives	36
Single-cell RNA sequencing identifies a subtype of FN1 + tumor-associated macrophages associated with glioma recurrence and as a biomarker for immunotherapy	35
Histamine N-methyltransferase (HNMT) as a potential auxiliary biomarker for predicting adaptability to anti-HER2 drug treatment in breast cancer patients	34
Imaging biomarkers for clinical applications in neuro-oncology: current status and future perspectives	34
Targeting serine-glycine-one-carbon metabolism as a vulnerability in cancers	34
Soluble PD-L1 as a novel biomarker predicts poor outcomes and disease progression in de novo myelodysplastic syndromes	34
Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence	34
High-throughput LDI MS technology decodes the distinct metabolic landscape of prostate cancer in a large-scale cohort	34
Baseline extracellular vesicle miRNA-30c and autophagic CTCs predict chemoradiotherapy resistance and outcomes in patients with lung cancer	34
MORF4L2 induces immunosuppressive microenvironment and immunotherapy resistance through GRHL2/MORF4L2/H4K12Ac/CSF1 axis in triple-negative breast cancer	34
Fatty acid metabolism shapes immune responses in chronic lymphocytic leukemia	34
Unlocking the power of extracellular vesicles: multi-omics integration for cancer biomarker discovery	33
Adipose-derived stem cell exosomes: mechanisms and therapeutic potentials in wound healing	33
Tobacco smoking associates with NF1 mutations exacerbating survival outcomes in gliomas	33
NLRP4 unlocks an NK/macrophages-centered ecosystem to suppress non-small cell lung cancer	32
Lysine methylation modifications in tumor immunomodulation and immunotherapy: regulatory mechanisms and perspectives	32
ZDHHC5: a pivotal palmitoyltransferase orchestrating signaling networks – unraveling mechanisms and therapeutic horizons	32
Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer	32
A plasma 9-microRNA signature for lung cancer early detection: a multicenter analysis	31
Targeted protein degradation in hematologic malignancies: clinical progression towards novel therapeutics	31
Plasma proteomics uncovers divergent molecular signatures in ischemic stroke and intracerebral hemorrhage	30
Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer	30
Prevalence and clinical significance of Claudin-3 expression in cancer: a tissue microarray study on 14,966 tumor samples	30
FGL1 and FGL2: emerging regulators of liver health and disease	29
RNA epigenetic modifications as dynamic biomarkers in cancer: from mechanisms to clinical translation	29
Functional heterogeneity of cancer-associated fibroblasts with distinct neoadjuvant immunotherapy plus chemotherapy response in esophageal squamous cell carcinoma	29
New cell sources for CAR-based immunotherapy	29
Extracellular matrix: unlocking new avenues in cancer treatment	29
Proteolysis-targeting chimera (PROTAC) in cancer: design principles and applications on “undruggable” targets	28
Challenges and advances for huntingtin detection in cerebrospinal fluid: in support of relative quantification	28
HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia	28
Association of CAR-T approval on outcomes in patients with diffuse large B-cell lymphoma at the population level in the United States	28
S100A9 as a potential novel target for experimental autoimmune cystitis and interstitial cystitis/bladder pain syndrome	27
Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs	27
Molecular PET imaging of integrin αvβ6 reveals biliary and fibrotic changes in preclinical MASH	27
EIF4A3-induced Circ_0001187 facilitates AML suppression through promoting ubiquitin-proteasomal degradation of METTL3 and decreasing m6A modification level mediated by miR-499a-5p/RNF113A pathway	26
Association between circulating ECM-associated molecules and cardiovascular outcomes in hemodialysis patients: a multicenter prospective cohort study	26
Correction: CRISPR/Cas-based CAR-T cells: production and application	25
T cells in cancer: mechanistic insights and therapeutic advances	25
TUG1: a potential endogenous reference gene for long noncoding RNA quantification in blood-based studies	25
METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer	25
USP21-EGFR-Lyn axis drives NSCLC progression and therapeutic potential of USP21 inhibition	25
Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia	24
Epigenetic biomarkers of progestin-resistance in endometriosis	24
Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape	24
Targeting TIGIT for cancer immunotherapy: recent advances and future directions	24
Microbiome multi-omics analysis reveals novel biomarkers and mechanisms linked with CD etiopathology	24
MiRNAs as potential therapeutic targets and biomarkers for non-traumatic intracerebral hemorrhage	24
THSD4 is a novel mediator of T cell exclusion and anti-PD-1 resistance in hormone receptor-positive breast cancer	23
Single-cell multi-omics analysis identifies SPP1+ macrophages as key drivers of ferroptosis-mediated fibrosis in ligamentum flavum hypertrophy	23
Toll-like receptor 3: a double-edged sword	23
Cervical cancer heterogeneity: a constant battle against viruses and drugs	23
A germline FLT3 variant in aplastic anemia	23
The multifaceted roles of cathepsins in immune and inflammatory responses: implications for cancer therapy, autoimmune diseases, and infectious diseases	23
Piwi-interacting RNA 775 (piR-775) predicts favorable prognosis and regulates cell cycle and DNA damage response pathways in breast cancer	23
Oncogenic alterations in advanced NSCLC: a molecular super-highway	23
PTK2 is a potential biomarker and therapeutic target for EGFR- or TLRs-induced lung cancer progression via the regulation of the cross-talk between EGFR- and TLRs-mediated signals	23
Decoding tumor angiogenesis: pathways, mechanisms, and future directions in anti-cancer strategies	23
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted	23